Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Interest Expenses (2016 - 2024)

Sunshine Biopharma's Interest Expenses history spans 11 years, with the latest figure at $8529.0 for Q4 2024.

  • For Q4 2024, Interest Expenses fell 71.67% year-over-year to $8529.0; the TTM value through Sep 2025 reached $8529.0, down 89.28%, while the annual FY2024 figure was $8774.0, 93.61% down from the prior year.
  • Interest Expenses reached $8529.0 in Q4 2024 per SBFM's latest filing, up from $245.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $195630.0 in Q2 2021 to a low of $2.0 in Q3 2022.
  • Average Interest Expenses over 5 years is $39296.4, with a median of $28328.0 recorded in 2022.
  • Peak YoY movement for Interest Expenses: crashed 100.0% in 2022, then surged 1926250.0% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $105436.0 in 2020, then crashed by 65.26% to $36630.0 in 2021, then fell by 27.53% to $26546.0 in 2022, then rose by 13.43% to $30110.0 in 2023, then crashed by 71.67% to $8529.0 in 2024.
  • Per Business Quant, the three most recent readings for SBFM's Interest Expenses are $8529.0 (Q4 2024), $245.0 (Q2 2024), and $49181.0 (Q1 2024).